TNFRSF11B and rheumatoid arthritis: Administration of either ETA or ADA led to a significant increase in serum PINP and OPG levels, and decrease in serum CTX-I levels in women with RA after 15 months of therapy (p < 0.001, p < 0.001, and p < 0.01, respectively; Figure 4a,b,d).